Dual-tracer radionuclide imaging in hyperparathyroidism: thallium-201 parathyroid scintigraphy revisited
Sign Up to like & getrecommendations! Published in 2020 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000001295
Abstract: Objectives 99mTc-sestamibi is the current radiopharmaceutical of choice for the localization of hyperactive lesions of the parathyroid glands in patients with hyperparathyroidism. However, there are multiple factors that adversely affect the accumulation and retention 99mTc-sestamibi… read more here.
Keywords: parathyroid; 201 parathyroid; thallium 201; hyperparathyroidism ... See more keywords